CapsulesClinical Overview
Pantoprazole (40mg gastro-resistant) and Cinitapride (3mg sustained-release) combines an irreversible H+/K+-ATPase inhibitor with a substituted benzamide prokinetic. Cinitapride acts as a 5-HT1 and 5-HT4 receptor agonist and a 5-HT2 receptor antagonist, accelerating gastric emptying and colonic transit while improving lower esophageal sphincter resting pressure. Indicated for gastroesophageal reflux disease, gastroparesis, and functional dyspepsia when single agents are insufficient.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily, 30 minutes before breakfast with water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Mild diarrhea, nausea, headache, abdominal cramps, transient drowsiness. Rare/Severe: Extrapyramidal reactions, hypersensitivity reactions, drug-induced liver injury.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in mechanical bowel obstruction, GI bleeding, and confirmed tardive dyskinesia. Avoid co-administration with strong CYP3A4 inhibitors (clarithromycin, itraconazole) which increase cinitapride plasma concentrations.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Pantoprazole Gastro Resistant Tablets 40 mg
Pantoprazole Gastro-Resistant Tablets (20mg, 40mg) is an oral substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It covalently binds to the H+/K+-ATPase system at cysteine 813 and 822 on parietal cells, suppressing both basal and stimulated hydrochloric acid secretion for over 24 hours. Indicated for the treatment of duodenal ulcers, gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions including Zollinger-Ellison syndrome.
Pantoprazole Injection 40mg
Pantoprazole for Injection (40mg vial) is an intravenous proton pump inhibitor on the WHO Model List of Essential Medicines. It irreversibly binds to H+/K+-ATPase proton pumps on parietal cells, achieving profound, immediate acid suppression. Indicated for short-term IV treatment of acute peptic ulcer bleeding, prevention of rebleeding following endoscopic hemostasis, severe erosive esophagitis in patients unable to take oral medications, and Zollinger-Ellison syndrome / hypersecretory states.
Pantoprazole 40mg (Gastro-resistant) + Domperidone 30mg (Prolonged Release) Capsules
Pantoprazole (20mg/40mg enteric-coated) and Domperidone (10mg/30mg sustained/prolonged-release) is a fixed-dose combination antiulcer and prokinetic therapy. Pantoprazole irreversibly binds to the gastric H+/K+-ATPase proton pump on parietal cells, suppressing basal and stimulated hydrochloric acid secretion for >24 hours. Domperidone is a peripheral dopamine D2 receptor antagonist that accelerates gastric emptying and increases lower esophageal sphincter (LES) tone without crossing the blood-brain barrier. Indicated for gastroesophageal reflux disease (GERD) with reflux esophagitis, non-ulcer dyspepsia, diabetic gastroparesis, and acid peptic disorders associated with nausea, fullness, or early satiety.
Pantoprazole 40mg (Enteric Coated) + Levosulpiride 75mg (Sustained Release) Capsules
Pantoprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) is a potent combination of a proton pump inhibitor and a prokinetic benzamide. Pantoprazole profoundly suppresses gastric acid synthesis by blocking H+/K+-ATPase pumps. Levosulpiride is the levorotatory enantiomer of sulpiride that selectively antagonizes dopamine D2 receptors in the enteric nervous system and acts as an agonist at 5-HT4 receptors, accelerating gastric and gallbladder emptying and improving antropyloric coordination. Indicated for severe GERD refractory to conventional prokinetics, diabetic gastroparesis, and functional dyspepsia with prominent postprandial distress syndrome.